Physician profile
Jack Kinder
NPI 1831199959
$8,294.33
in general payments reported to CMS, 2019-2025
35 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $658 · 2021: $1,334 · 2022: $1,406 · 2023: $1,342 · 2024: $1,483 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,873.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,719.10 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,051.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $698.90 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $698.76 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $433.22 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $412.43 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $370.91 | 2019-2023 | Verquvo, Belsomra |
| Abbvie INC. | $273.65 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $273.02 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $260.74 | 2019-2022 | |
| Amgen INC. | $249.38 | 2019-2025 | Repatha, Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $234.08 | 2024-2025 | Voquezna |
| Abbott Laboratories | $198.42 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $182.30 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $160.14 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $152.24 | 2023 | Quviviq |
| Dexcom, INC. | $126.68 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $123.04 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $101.07 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $92.68 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.66 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $63.29 | 2020-2023 | Eliquis |
| Genentech USA, INC. | $47.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.08 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.23 | 2021-2022 | |
| Recor Medical INC | $30.40 | 2025 | Paradise Ultrasound Renal Denervation System |
| Biogen, INC. | $30.15 | 2021 | |
| Horizon Therapeutics Plc | $27.54 | 2020 | |
| Allergan, INC. | $25.31 | 2019-2020 | |
| Optinose US, INC. | $24.89 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $15.96 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.92 | 2021 | |
| Redhill Biopharma INC. | $14.31 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.52 | 2021 | |
| Esperion Therapeutics, INC. | $13.07 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Kinder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.